Status:
COMPLETED
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
Lead Sponsor:
Pfizer
Conditions:
Huntington's Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
Eligibility Criteria
Inclusion
- Must have a diagnosis of Huntington's Disease
- a CAG repeat expansion equal or great than 39
- a Unified Huntington Disease Rating Scale (UHDRS) Total Motor Score equal or greater than 5 and less than 60
- a UHDRS Total Functional Capacity equal or greater than 9
Exclusion
- Subjects with evidence or history of severe acute or chronic medical condition or laboratory abnormality, or significant neurological disorder other than HD.
- Treatment with any antipsychotic medication within 5 weeks of enrollment
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01806896
Start Date
September 1 2013
End Date
January 1 2015
Last Update
December 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre d'Investigation Clinique (CIC)/ Institut du Cerveau et de la Möelle Epinière (ICM)
Paris, France, 75651